Cullinan Therapeutics, Inc.

CGEM · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$51-$70-$49-$48
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$10$9$10
Change in WC$6$4-$2$5
Other Non-Cash$8-$2-$2-$4
Operating Cash Flow-$37-$58-$43-$37
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$13-$79-$126-$168
Inv. Sales/Matur.$80$132$163$184
Other Inv. Act.-$0$0$0$0
Investing Cash Flow$67$53$37$16
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$2
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$0$0$0$2
Forex Effect$0$0$0$0
Net Chg. in Cash$31-$4-$6-$19
Supplemental Information
Beg. Cash$73$77$83$102
End Cash$103$73$77$83
Free Cash Flow$0-$58-$43-$37
Cullinan Therapeutics, Inc. (CGEM) Financial Statements & Key Stats | AlphaPilot